GROUNDBREAKING HAE Treatment
ANDEMBRY transforms HAE management by targeting the HAE pathway at the top
ANDEMBRY Provides Significant Reduction in HAE Attacks
A median reduction of >99% was calculated because at least half of the ANDEMBRY-treated patients experienced a complete reduction in monthly HAE attack rates compared to placebo. Patients receiving ANDEMBRY in the clinical trial experienced an adjusted average of 89% (LS; least squares) reduction in monthly HAE attack rate compared to placebo.
* With all HAE medications, attacks can still occur. Patients should always have a rescue medication.
† At 6 months.
LS, least squares
Attack reduction has been maintained throughout ongoing clinical trials§
§ 2+ years and counting.
The Only Once-Monthly Dosing
From The Start For All Patients
Subcutaneous self-injection delivered in ≤15 seconds via a convenient autoinjector
No reports of injection-site pain¶
¶ In the VANGUARD pivotal phase 3 trial. Patients in the pivotal study and open-label extension study experienced injection-site redness, itching, and bruising.
Innovation in Action
Only ANDEMBRY, a monoclonal antibody, inhibits FXIIa at the top of the HAE pathway